(the “Company” or “Lexaria”) reports that the joint venture with Enertopia Corp has begun a National Medical Marijuana Awareness and Outreach Strategy headed by Maureen McGrath, RN.
As part of the plan, Maureen will be educating physicians, pharmacists and other health care practitioners, as well as the public on the benefits and cautions related to the responsible use of medical Marijuana for patients in need. Lexaria intends for Maureen to reach out via town hall – style meetings as well as through media outlets to liase with those persons with interest in the medical Marijuana field.
Maureen hosts the popular CKNW Sunday Night Sex Show a lively listener call-in weekly radio program and is a frequent health contributor to a number of other radio shows and magazines. A sought after lecturer she presents to the public as well as undergraduate and medical students at the University of British Columbia and Simon Fraser University. She educates physicians, nurses, allied health, industry, government and the public on all matters related to sexual health. Maureen’s impressive background includes quality of life research in spinal cord injury, advocacy and business development in the biotechnical industry. Maureen is a guest columnist for the 24Hours Newspaper.
Maureen is well-respected health care professional and leader in her field and was a 2013 YWCA Women of Distinction finalist for health and wellness. She is the Chair of the BC Chapter of Canadian Nurse Continence Advisors and specializes in sexual health for men and women at Cross Roads Clinic in Vancouver. Maureen is on the board of the College of Midwives of British Columbia and on the advisory board for the Be More Than A Bystander Program with EVA BC and the BC Lions. She is a long time mentor with Minerva’s “Women Helping Women Work” Program. She is passionate about raising awareness about violence against women.
“I am excited at the opportunity to help educate the healthcare community on the potential benefits of Medical Marijuana and its many uses,” stated Maureen McGrath. “Lexaria has adopted an industry-leading policy of an unwillingness to sell marijuana to youth under the age of 21, and I support this position whole-heartedly.”
“Lexaria welcomes Maureen to our team and I look forward to working with her to expand our involved and committed community,” said CEO Chris Bunka.
Lexaria’s shares are quoted in the USA with symbol LXRP and in Canada with symbol LXX. The company searches for projects that could provide potential above-market returns.
To learn more about Lexaria Corp. visit www.lexariabioscience.com.
FOR FURTHER INFORMATION PLEASE CONTACT:
Chairman & CEO
This release includes forward-looking statements. Statements which are not historical facts are forwardlooking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Access to capital, or lack thereof, is a major risk and there is no assurance that the Company will be able to raise required working capital. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company’s public announcements and filings.
There is no assurance that the medical marijuana, CBD sector, or alternative health businesses will provide any benefit to Lexaria, or that the Company will experience any growth through participation in these sectors. There is no assurance that existing capital is sufficient for the Company’s needs or that it will need to attempt to raise additional capital. There is no assurance that any cannabinoid-based product will promote, assist, or maintain any beneficial human health conditions whatsoever. No
statement herein has been evaluated by the Food and Drug Administration (FDA). ViPovaTM products are not intended to diagnose, treat, cure or prevent any disease.
The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release